anticholinergics + monoamine oxidase B inhibitors

This refers to a **combination of two classes of drugs**—anticholinergics and monoamine oxidase B (MAO-B) inhibitors—rather than a single agent or a uniquely branded combination. - **Anticholinergics** block the action of acetylcholine at muscarinic receptors in the central and peripheral nervous systems, reducing cholinergic activity. They are used primarily to manage tremor and rigidity in Parkinson's disease. - **MAO-B inhibitors** (such as selegiline, rasagiline, and safinamide) inhibit the MAO-B enzyme in the brain, which is responsible for breaking down dopamine. By blocking this enzyme, they increase dopamine availability in the striatum, thereby helping to manage motor symptoms in Parkinson’s disease[1][2][3][6]. There are no specific, co-formulated or uniquely named pharmaceutical products combining these classes; they may be co-prescribed in clinical practice to manage symptoms of Parkinson’s disease.